You just read:

Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Aug 07, 2017, 03:00 ET